Physician profile
Jonathan Ray Varney
NPI 1538262423
$1,903.07
in general payments reported to CMS, 2019-2025
11 companies · $866 in 2025
The $866 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $580 · 2022: $238 · 2023: $219 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $331.56 | 2021-2025 | |
| Novo Nordisk INC | $328.26 | 2022-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $235.76 | 2022-2025 | |
| Gilead Sciences, INC. | $152.24 | 2022-2025 | Yeztugo |
| Amgen INC. | $148.03 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Axsome Therapeutics, INC. | $120.69 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $118.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $116.76 | 2021 | |
| Lilly USA, LLC | $116.50 | 2025 | Zepbound |
| Esperion Therapeutics, INC. | $110.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Varney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.